Clinical Trial Update: Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial of Baminercept for primary Sjögren's syndrome was terminated; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome

Drugs mentioned

• Baminercept (baminercept)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Primary Sjögren's Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2016-03-23